Market closedNon-fractional
Werewolf Therapeutics/HOWL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Ticker
HOWL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Watertown, United States
Employees
46
Website
werewolftx.com
HOWL Metrics
BasicAdvanced
$90M
Market cap
-
P/E ratio
-$1.11
EPS
0.62
Beta
-
Dividend rate
Price and volume
Market cap
$90M
Beta
0.62
Financial strength
Current ratio
6.707
Quick ratio
6.598
Long term debt to equity
32.629
Total debt to equity
43.603
Interest coverage (TTM)
-10.97%
Management effectiveness
Return on assets (TTM)
-15.24%
Return on equity (TTM)
-34.84%
Valuation
Price to revenue (TTM)
4.79
Price to book
0.77
Price to tangible book (TTM)
0.77
Price to free cash flow (TTM)
-2.006
Growth
Revenue change (TTM)
-22.26%
Earnings per share change (TTM)
-32.23%
3-year earnings per share growth
-78.69%
What the Analysts think about HOWL
Analyst Ratings
Majority rating from 6 analysts.
HOWL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$700K
-53.33%
Net income
-$16M
34.17%
Profit margin
-2,300.00%
187.50%
HOWL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.23
-$0.33
-$0.39
-
Expected
-$0.42
-$0.39
-$0.43
-$0.35
-$0.37
Surprise
-66.82%
-41.74%
-23.89%
11.75%
-
HOWL News
AllArticlesVideos
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
GlobeNewsWire·2 weeks ago
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
GlobeNewsWire·1 month ago
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Werewolf Therapeutics stock?
Werewolf Therapeutics (HOWL) has a market cap of $90M as of July 06, 2024.
What is the P/E ratio for Werewolf Therapeutics stock?
The price to earnings (P/E) ratio for Werewolf Therapeutics (HOWL) stock is 0 as of July 06, 2024.
Does Werewolf Therapeutics stock pay dividends?
No, Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Werewolf Therapeutics dividend payment date?
Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders.
What is the beta indicator for Werewolf Therapeutics?
Werewolf Therapeutics (HOWL) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Werewolf Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.